Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis

Dimopoulos, Meletios A.; Niesvizky, Ruben; Weisel, Katja; Siegel, David S.; Hajek, Roman; Mateos, Maria-Victoria; Cavo, Michele; Huang, Mei; Zahlten-Kumeli, Anita; Moreau, Philippe

dc.contributor.author	Weisel, Katja
dc.date.accessioned	2020-10-06T06:32:30Z
dc.date.available	2020-10-06T06:32:30Z
dc.date.issued	2020
dc.identifier.issn	2044-5385
dc.identifier.uri	http://hdl.handle.net/10900/107526
dc.language.iso	en	de_DE
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/s41408-020-0300-y	de_DE
dc.subject.ddc	610	de_DE
dc.title	Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 ARROW study subgroup analysis	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200715072417_01233
utue.personen.roh	Dimopoulos, Meletios A.
utue.personen.roh	Niesvizky, Ruben
utue.personen.roh	Weisel, Katja
utue.personen.roh	Siegel, David S.
utue.personen.roh	Hajek, Roman
utue.personen.roh	Mateos, Maria-Victoria
utue.personen.roh	Cavo, Michele
utue.personen.roh	Huang, Mei
utue.personen.roh	Zahlten-Kumeli, Anita
utue.personen.roh	Moreau, Philippe
dcterms.isPartOf.ZSTitelID	Blood Cancer Journal	de_DE
dcterms.isPartOf.ZS-Issue	Article 35	de_DE
dcterms.isPartOf.ZS-Volume	10	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE